Abelacimab

4 trials 1 recruiting

Filter these 4 trials by condition, phase, country and more.

Open in Search →

4 Registered trials

1 Recruiting

3 Completed trials

1 Sponsors

20 Countries

Phase III

Phase II/III

Phase II

Phase III: 1 Phase II/III: 2 Phase II: 1

Oversight events:

2 serious breaches 12 temporary halts across 2 trials

View oversight register →

Indications tested

Atrial fibrillation 2

Sponsors using this IMP

Anthos Therapeutics Inc. 4

All trials

4 total

A Phase 3, multicenter, randomized, double-blind, placebo-controlled, parallel-group study to evaLuate the effIcacy and safety of abeLacimab… Recruiting

2023-503224-66-00 Phase III 15 countries Anthos Therapeutics Inc.
A study to compare how safe and well tolerated study drug Abelacimab (MAA868) is compared to another drug called Rivaroxaban in patients wit… Ended

2023-509066-38-00 Phase II 3 countries Anthos Therapeutics Inc.
A multicenter, randomized, open-label, blinded endpoint evaluation, phase 3 study comparing the effect of abelacimab relative to dalteparin … Ended

2024-513992-42-00 Phase II/III 12 countries Anthos Therapeutics Inc.
A multicenter, randomized, open-label, blinded endpoint evaluation, phase 3 study comparing the effect of abelacimab relative to apixaban on… Ended

2023-509569-19-00 Phase II/III 12 countries Anthos Therapeutics Inc.

Showing 1–4 of 4 trials

← All drugs A–Z